Description
Belantamab mafodotin is indicated for the treatment of adults with relapsed or refractory multiple myeloma who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. However, the phase III DREAMM-3 trial published in 2023, comparing patients with relapsed or refractory multiple myeloma receiving belantamab mafodotin to pomalidimide and dexamethasone did not demonstrate a clinical benefit for belantamab mafodotin. Due to this trial results, the manufacturer is voluntarily withdrawing belantamab mafodotin from the market.
belantamab mafodotin-blmf is available in India on request-
Lucknow Speciality Pharma is the leading Pharma brand and one of the most leading Pharma Wholesalers in Lucknow. We are expanding our reach across India. To get “BLENREP (belantamab mafodotin-blmf) for injection“, patients can simply fill the order form or can send mail at info@lucknowpharma.com. Patients can also send WhatsApp messages to +91-9555306364, The order will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.





